Disease models for the development of therapies for lysosomal storage diseases

Annals of the New York Academy of Sciences

Volumn 1371, Issue 1, 2016, Pages 15-29

  Xu, Miao ^a,b   Motabar, Omid ^a   Ferrer, Marc ^a   Marugan, Juan J ^a   Zheng, Wei ^a   Ottinger, Elizabeth A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

animal models; cell based disease model; induced pluripotent stem cells; lysosomal storage diseases; therapeutic development

Indexed keywords

ARTICLE; DISEASE COURSE; DISEASE MODEL; HIGH THROUGHPUT SCREENING; HUMAN; INDUCED PLURIPOTENT STEM CELL; LYSOSOME STORAGE DISEASE; NONHUMAN; PATHOGENESIS; PHENOTYPE;

EID: 84977544497     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13052     Document Type: Article

References (117)

1. Kingma, S.D., O.A. Bodamer & F.A. Wijburg. 2015. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract. Res. Clin. Endocrinol. Metab. 29: 145–157.
2. Meikle, P.J. et al. 1999. Prevalence of lysosomal storage disorders. JAMA 281: 249–254.
3. Sanderson, S. et al. 2006. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch. Dis. Child. 91: 896–899.
4. Mehta, A. et al. 2006. “History of lysosomal storage diseases: an overview.” In Fabry Disease: Perspectives from 5 Years of FOS. A., Mehta, M. Beck & G. Sunder-Plassmann, Eds.: 1–26. Oxford: Oxford PharmaGenesis.
5. Appelqvist, H. et al. 2013. The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell Biol. 5: 214–226.
6. Parenti, G., G. Andria & A. Ballabio. 2015. Lysosomal storage diseases: from pathophysiology to therapy. Annu. Rev. Med. 66: 471–486.
7. Schultz, M.L. et al. 2011. Clarifying lysosomal storage diseases. Trends Neurosci. 34: 401–410.
8. Sidransky, E. 2012. Gaucher disease: insights from a rare Mendelian disorder. Discov. Med. 14: 273–281.
9. Stampfer, M. et al. 2013. Niemann–Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators. Orphanet J. Rare Dis. 8: 35.
10. Mechler, K. et al. 2015. Pressure for drug development in lysosomal storage disorders—a quantitative analysis thirty years beyond the US orphan drug act. Orphanet J. Rare Dis. 10: 46.
11. U.S. Food and Drug Administration: Center for Drug Evaluation and Research. 2015. Novel drugs summary for 2015. Accessed January 10, 2016. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm.
12. Hollak, C.E. & F.A. Wijburg. 2014. Treatment of lysosomal storage disorders: successes and challenges. J. Inherit. Metab. Dis. 37: 587–598.
13. European Medicines Agency. 2015. Human medicines: highlights of 2015. Accessed January 20, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Brochure/2016/01/WC500199664.pdf.
14. Scarpa, M. et al. 2015. Neuronopathic lysosomal storage disorders: approaches to treat the central nervous system. Best Pract. Res. Clin. Endocrinol. Metab. 29: 159–171.
15. Boland, B. & F.M. Platt. 2015. Bridging the age spectrum of neurodegenerative storage diseases. Best Pract. Res. Clin. Endocrinol. Metab. 29: 127–143.
16. Coutinho, M.F. & S. Alves. 2016. From rare to common and back again: 60 years of lysosomal dysfunction. Mol. Genet. Metab. 117: 53–65.
17. Boyd, R.E. & K.J. Valenzano. 2014. Correction of lysosomal dysfunction as a therapeutic strategy for neurodegenerative diseases. Bioorg. Med. Chem. Lett. 24: 3001–3005.
18. Zhang, L., R. Sheng & Z. Qin. 2009. The lysosome and neurodegenerative diseases. Acta Biochim. Biophys. Sin. (Shanghai) 41: 437–445.
19. Arrowsmith, J. 2011. Trial watch: phase II failures: 2008–2010. Nat. Rev. Drug Discov. 10: 328–329.
20. Arrowsmith, J. 2011. Trial watch: phase III and submission failures: 2007–2010. Nat. Rev. Drug Discov. 10: 87.
21. Haskins, M.E., U. Giger & D.F. Patterson. 2006. “Animal models of lysosomal storage diseases: their development and clinical relevance.” In Fabry Disease: Perspectives from 5 Years of FOS. A. Mehta, M. Beck & G. Sunder-Plassmann, Eds.: 1–54. Oxford: Oxford PharmaGenesis.
22. Vaquer, G. et al. 2013. Animal models for metabolic, neuromuscular and ophthalmological rare diseases. Nat. Rev. Drug Discov. 12: 287–305.
23. Kol, A. et al. 2015. Companion animals: translational scientist's new best friends. Sci. Transl. Med. 7: 308ps321.
24. Augustine, E.F., H.R. Adams & J.W. Mink. 2013. Clinical trials in rare disease: challenges and opportunities. J. Child Neurol. 28: 1142–1150.
25. Huang, H.P., C.Y. Chuang & H.C. Kuo. 2012. Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases. Stem Cell Res. Ther. 3: 34.
26. Efeyan, A., W.C. Comb & D.M. Sabatini. 2015. Nutrient-sensing mechanisms and pathways. Nature 517: 302–310.
27. Abraham, R.T. 2015. Cell biology. Making sense of amino acid sensing. Science 347: 128–129.
28. Korolchuk, V.I. et al. 2011. Lysosomal positioning coordinates cellular nutrient responses. Nat. Cell Biol. 13: 453–460.
29. Betz, C. & M.N. Hall. 2013. Where is mTOR and what is it doing there? J. Cell Biol. 203: 563–574.
30. Feng, Y. et al. 2014. The machinery of macroautophagy. Cell Res. 24: 24–41.
31. Samie, M. et al. 2013. A TRP channel in the lysosome regulates large particle phagocytosis via focal exocytosis. Dev. Cell 26: 511–524.
32. Tam, C. et al. 2010. Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. J. Cell Biol. 189: 1027–1038.
33. Settembre, C. et al. 2011. TFEB links autophagy to lysosomal biogenesis. Science 332: 1429–1433.
34. Sardiello, M. et al. 2009. A gene network regulating lysosomal biogenesis and function. Science 325: 473–477.
35. Settembre, C. et al. 2012. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31: 1095–1108.
36. Martina, J.A. et al. 2014. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci. Signal. 7: ra9.
37. Awad, O. et al. 2015. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum. Mol. Genet. 24: 5775–5788.
38. Siddiqui, A. et al. 2015. Mitochondrial quality control via the PGC1α–TFEB signaling pathway is compromised by parkin Q311X mutation but independently restored by rapamycin. J. Neurosci. 35: 12833–12844.
39. Aerts, J.M. et al. 2011. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J. Inherit. Metab. Dis. 34: 605–619.
40. Vanier, M.T. 2010. Niemann–Pick disease type C. Orphanet J. Rare Dis. 5: 16.
41. Sarna, J.R. et al. 2003. Patterned Purkinje cell degeneration in mouse models of Niemann–Pick type C disease. J. Comp. Neurol. 456: 279–291.
42. Xu, M. et al. 2012. δ-Tocopherol reduces lipid accumulation in Niemann–Pick type C1 and Wolman cholesterol storage disorders. J. Biol. Chem. 287: 39349–39360.
43. Medina, D.L. et al. 2011. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev. Cell 21: 421–430.
44. Wong, E. & A.M. Cuervo. 2010. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13: 805–811.
45. Alvarez, A.R. et al. 2008. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann–Pick type C disease. FASEB J. 22: 3617–3627.
46. Cancino, G.I. et al. 2008. STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's β-amyloid deposits. Brain 131: 2425–2442.
47. Malnar, M. et al. 2014. Bidirectional links between Alzheimer's disease and Niemann–Pick type C disease. Neurobiol. Dis. 72(Pt. A): 37–47.
48. Sidransky, E. & G. Lopez. 2012. The link between the GBA gene and parkinsonism. Lancet Neurol. 11: 986–998.
49. Katz, R. 2004. FDA: evidentiary standards for drug development and approval. NeuroRx 1: 307–316.
50. Ratko, T.A. et al. 2013. Enzyme-replacement therapies for lysosomal storage diseases. Agency for Healthcare Research and Quality (US), Rockville, MD.
51. Desnick, R.J. & E.H. Schuchman. 2012. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13: 307–335.
52. Fratantoni, J.C., C.W. Hall & E.F. Neufeld. 1968. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162: 570–572.
53. Begley, D.J., C.C. Pontikis & M. Scarpa. 2008. Lysosomal storage diseases and the blood–brain barrier. Curr. Pharm. Des. 14: 1566–1580.
54. Kakkis, E.D. et al. 1996. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 58: 156–167.
55. Kishnani, P.S. et al. 2015. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol. Genet. Metab. 117: 66–83.
56. Rombach, S.M. et al. 2013. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J. Rare Dis. 8: 29.
57. Beutler, E. 2006. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol. Genet. Metab. 88: 208–215.
58. Weinreb, N.J. et al. 2002. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. 113: 112–119.
59. Anderson, L.J. et al. 2014. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J. Inherit. Metab. Dis. 37: 945–952.
60. Valayannopoulos, V. & F.A. Wijburg. 2011. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 50(Suppl. 5): v49–v59.
61. Kakkis, E.D. et al. 2001. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344: 182–188.
62. Dickson, P.I. & A.H. Chen. 2011. Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr. Pharm. Biotechnol. 12: 946–955.
63. Parenti, G., G. Andria & K.J. Valenzano. 2015. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol. Ther. 23: 1138–1148.
64. Cox, T. et al. 2000. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481–1485.
65. Sechi, A., A. Dardis & B. Bembi. 2016. Profile of eliglustat tartrate in the management of Gaucher disease. Ther. Clin. Risk Manag. 12: 53–58.
66. Patterson, M.C. et al. 2007. Miglustat for treatment of Niemann–Pick C disease: a randomised controlled study. Lancet Neurol. 6: 765–772.
67. Zimran, A. & D. Elstein. 2003. Gaucher disease and the clinical experience with substrate reduction therapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358: 961–966.
68. Kuter, D.J. et al. 2013. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol. Dis. 51: 116–124.
69. Rosenbaum, A.I. & F.R. Maxfield. 2011. Niemann–Pick type C disease: molecular mechanisms and potential therapeutic approaches. J. Neurochem. 116: 789–795.
70. Valenzano, K.J. et al. 2011. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev. Technol. 9: 213–235.
71. Bendikov-Bar, I. et al. 2013. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50: 141–145.
72. Panicker, L.M. et al. 2014. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells 32: 2338–2349.
73. Zimran, A., G. Altarescu & D. Elstein. 2013. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis. 50: 134–137.
74. Zheng, W. et al. 2007. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 104: 13192–13197.
75. Goldin, E. et al. 2012. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS One 7: e29861.
76. Geng, H. et al. 2011. Novel patient cell-based HTS assay for identification of small molecules for a lysosomal storage disease. PLoS One 6: e29504.
77. Ribbens, J. et al. 2013. A high-throughput screening assay using Krabbe disease patient cells. Anal. Biochem. 434: 15–25.
78. Cherry, A.B. & G.Q. Daley. 2013. Reprogrammed cells for disease modeling and regenerative medicine. Annu. Rev. Med. 64: 277–290.
79. Inoue, H. et al. 2014. iPS cells: a game changer for future medicine. EMBO J. 33: 409–417.
80. Bellin, M. et al. 2012. Induced pluripotent stem cells: the new patient? Nat. Rev. Mol. Cell Biol. 13: 713–726.
81. Zheng, W., N. Thorne & J.C. McKew. 2013. Phenotypic screens as a renewed approach for drug discovery. Drug Discov. Today 18: 1067–1073.
82. Kawagoe, S. et al. 2013. Morphological features of iPS cells generated from Fabry disease skin fibroblasts using Sendai virus vector (SeVdp). Mol. Genet. Metab. 109: 386–389.
83. Panicker, L.M. et al. 2012. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 109: 18054–18059.
84. Tiscornia, G. et al. 2013. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum. Mol. Genet. 22: 633–645.
85. Aflaki, E. et al. 2014. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci. Transl. Med. 6: 240ra273.
86. Schondorf, D.C. et al. 2014. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5: 4028.
87. Sgambato, J.A. et al. 2015. Gaucher disease-induced pluripotent stem cells display decreased erythroid potential and aberrant myelopoiesis. Stem Cells Transl. Med. 4: 878–886.
88. Son, M.Y. et al. 2015. A novel human model of the neurodegenerative disease GM1 gangliosidosis using induced pluripotent stem cells demonstrates inflammasome activation. J. Pathol. 237: 98–110.
89. Tolar, J. et al. 2011. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood 117: 839–847.
90. Lemonnier, T. et al. 2011. Modeling neuronal defects associated with a lysosomal disorder using patient-derived induced pluripotent stem cells. Hum. Mol. Genet. 20: 3653–3666.
91. Griffin, T.A., H.C. Anderson & J.H. Wolfe. 2015. Ex vivo gene therapy using patient iPSC-derived NSCs reverses pathology in the brain of a homologous mouse model. Stem Cell Reports 4: 835–846.
92. Yu, D. et al. 2014. Niemann–Pick disease type C: induced pluripotent stem cell-derived neuronal cells for modeling neural disease and evaluating drug efficacy. J. Biomol. Screen. 19: 1164–1173.
93. Efthymiou, A.G. et al. 2015. Rescue of an in vitro neuron phenotype identified in Niemann–Pick disease, type C1 induced pluripotent stem cell–derived neurons by modulating the WNT pathway and calcium signaling. Stem Cells Transl. Med. 4: 230–238.
94. Maetzel, D. et al. 2014. Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann–Pick type C patient-specific iPS cells. Stem Cell Reports 2: 866–880.
95. Trilck, M. et al. 2013. Niemann–Pick type C1 patient-specific induced pluripotent stem cells display disease specific hallmarks. Orphanet J. Rare Dis. 8: 144.
96. Higuchi, T. et al. 2014. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs. Mol. Genet. Metab. 112: 44–48.
97. Huang, H.P. et al. 2011. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum. Mol. Genet. 20: 4851–4864.
98. Raval, K.K. et al. 2015. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. J. Biol. Chem. 290: 3121–3136.
99. Sato, Y. et al. 2015. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol. Ther. Methods Clin. Dev. 2: 15023.
100. 2+ homeostasis, autophagy, and CLN3 protein function. J. Biol. Chem. 290: 14361–14380.
101. Lojewski, X. et al. 2014. Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Hum. Mol. Genet. 23: 2005–2022.
102. Lieu, P.T. et al. 2013. Generation of induced pluripotent stem cells with CytoTune, a non-integrating Sendai virus. Methods Mol. Biol. 997: 45–56.
103. Pastores, G.M., P.A. Torres & B.J. Zeng. 2013. Animal models for lysosomal storage disorders. Biochemistry (Mosc.) 78: 721–725.
104. Xu, Y.H. et al. 2003. Viable mouse models of acid β-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol. 163: 2093–2101.
105. Farfel-Becker, T., E.B. Vitner & A.H. Futerman. 2011. Animal models for Gaucher disease research. Dis. Model Mech. 4: 746–752.
106. Hemsley, K.M. & J.J. Hopwood. 2010. Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J. Inherit. Metab. Dis. 33: 363–371.
107. Haskins, M. 2009. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J. 50: 112–121.
108. Kakkis, E.D. et al. 2001. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol. Genet. Metab. 72: 199–208.
109. Dierenfeld, A.D. et al. 2010. Replacing the enzyme α-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci. Transl. Med. 2: 60ra89.
110. Auclair, D. et al. 2012. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr. Res. 71: 39–45.
111. Ruane, T. et al. 2015. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6 months of therapy in cats using different IV infusion durations. Mol. Genet. Metab. 117: 157–163.
112. Marshall, N.R. et al. 2015. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Exp. Neurol. 263: 79–90.
113. Vite, C.H. et al. 2013. Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I. Comp. Med. 63: 163–173.
114. Katz, M.L. et al. 2014. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). J. Neurosci. Res. 92: 1591–1598.
115. Ottinger, E.A. et al. 2014. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann–Pick type C1 disease. Curr. Top. Med. Chem. 14: 330–339.
116. Vite, C.H. et al. 2015. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann–Pick type C1 disease. Sci. Transl. Med. 7: 276ra226.
117. Tortelli, B. et al. 2014. Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann–Pick C1 (NPC1). Hum. Mol. Genet. 23: 6022–6033.